IMUX Immunic, Inc.
USHealthcareAs of 2026-10-08
Why IMUX matters now
Immunic, Inc. (IMUX) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.56 with -0.92% on the session and $103.0M in market capitalization; recent performance reads 1-month +22.41% and YTD +165.92%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-32.6M, and EPS of $-1.08. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -58.1%.
The latest indexable market news headline is "Immunic to present four vidofludimus calcium abstracts at MSToronto2026" from Proactive Investors.
Additional event context on this page matters because analyst consensus is Buy with a median target of $19.00; recent insider activity includes Lundgren Erik filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.83
P/S
0.00
EV/EBITDA
0.44
DCF Value
$0.60
FCF Yield
-58.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-220.7%
ROA
-55.0%
ROIC
-72.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-32.6M | $-1.08 |
| Q4 2025 | $0.00 | $-19.3M | $-1.60 |
| FY 2025 | $0.00 | $-97.2M | $-6.24 |
| Q3 2025 | $0.00 | $-25.6M | $-1.30 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$14.50
Target (Median)
$19.00
Target Range
$2.50 - $22.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.39
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.